Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.

摘要: Thirty-two patients with refractory acute myeloid leukemia (AML) received salvage therapy a single course of mitoxantrone 6 mg/m2 intravenous (IV) bolus, etoposide 80 IV for period 1 hour, and cytarabine (Ara-C) g/m2 hours daily days (MEC). Eighteen were primarily resistant to conventional daunorubicin Ara-C induction treatment; eight had relapsed within months from initial remission; six after bone marrow transplantation (BMT) procedure. Overall, 21 (66%) achieved complete remission (CR), two (6%) died infection during induction, nine (28%) disease. Age greater than 50 years was the only factor predictive significantly lower response rate (P = .03). The median duration 16 weeks; overall survival 36 weeks. Severe myelosuppression observed in all resulting fever or documented infections 91% patients. Nonhematologic toxicity was...